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We describe the chemical synthesis and binding analysis of functionalizable rigid and flexible core trivalent sialosides bearing 
oligoethylene glycol (OEG) spacers interacting with spike proteins of influenza A virus (IAV) X31. Although the flexible tris-
based trivalent sialosides achieved micromolar binding constants, a trivalent binder based on a rigid adamantane core 
dominated flexible tripodal compounds with micromolar binding and hemagglutination inhibition constants. Simulation studies 
indicated increased conformational penalties for long OEG spacers. Using a systematic approach with molecular modeling and 
simulations as well as biophysical analysis, our findings emphasize on the importance of the scaffold rigidity and the challenges 
associated with the spacer length optimization. 
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Introduction 
Annually, seasonal influenza infections pose a great burden to global health and economy affecting up to 15% of the 
world population resulting in more than 500,000 deaths per year worldwide.[1] High mutation rates of this virus limit the 
use of available antiviral agents for a long-lasting application. Thus, there is urgent need for the development of novel 
antiviral drugs and therapies. A well-known strategy is the application of biomimetic binding inhibitors, acting as decoy 
molecules to prevent viral attachment to host cells. The latter is mediated by multivalent interaction of the homotrimeric 
hemagglutinin (HA) spike protein that is highly abundant on the viral surface with terminal sialic acids of glycostructures 
on the host cell plasma membrane.[2] Each monomer of the HA trimer has a receptor binding site (RBS) for sialic acid 
(SA). Inhibitors displaying SA moieties and thus competing with virus receptors on host cells, have been successfully 
implemented in various studies.[2b] Recently, Bandlow et al. reported on micromolar binding constants with bivalent 
sialyllactose derivatives based on DNA-PNA complexes.[3] Further, Bhatia et al. reported on nanomolar inhibitors of 
influenza virus infection with linear and dendritic polyglycerol based multivalent sialosides.[4] However, only few 
examples demonstrated the design of a trivalent binder, which is based on a rational design to match the geometric and 
topological situation on HA.[3, 5]  
As revealed from the crystal structure of HA from a human pathogenic H3N2 strain (pdb:1hgg), the planar distance 
between two SA-binding sites on a single HA trimer is around 4-5 nm (Figure 1).[6]  HA trimers are densely packed in 
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the viral envelope  and two adjacent HA3 are 10-12 nm centrally apart as determined from electron microscopy 
imaging.[7] Considering this spatial HA organization, a high affinity trivalent SA binder can be hypothetically designed by 
choosing an appropriate spacer to bring three covalently connected SA units in the right geometry matching that of the 
RBSs of HA3. Waldmann et al. explored trivalent SA presenting glycopeptide conjugates for targeting HA trimers of 
influenza A virus type H5 and obtained a binding constant of 446 nM from surface plasmon resonance (SPR) 
measurements, which is a 4000-fold increase compared to the monomeric binder methyl 2-methyl-α-d-N-
acetylneuraminide (Neu5Acα2Me) or methyl sialic acid respectively.  However, the inhibition values were still weak and 
in the micromolar range in saturation-transfer difference (STD) NMR based competition experiments. Nishimura and 
colleagues devised a glycopeptide possessing a cyclic peptides as scaffold [Neu5Acα(2,3)Galβ(1,4)Glc]  to display 
three sialotrisaccharide units at the termini.[8] In further studies, Nishimura et al. prepared trivalent sialyllactosides using 
trisphenol and trisaniline as cores and extended the length of the spacer with ethylenglycol trimers (EG3), glutamine, 
and C6 to partially compensate for the smaller scaffold.[9] These studies indicated that the design of trivalent binders is 
still challenging and that there are still several unknown parameters to finetune a trivalent binder for an optimal 
interaction with HA. 
In this study, we address the relevance of the flexibility of the anchor point carrying the sialoside residues for optimal 
interaction with HA. Furthermore, we varied the spacer length on both a rigid and a flexible core system to adjust the 
receptor spacing to match the given RBS distribution on HA trimers. The OEG spacers have been used due to their 
hydrophilicity and biocompatibility. However, the drawback of long OEG spacers is their high tendency to form globular 
structures, hampering an orchestral receptor orientation. OEG spacer containing HA-binders were implemented first by 
Knowles et al. for the synthesis of bivalent sialosides that showed 100-fold increased hemagglutination inhibition 
against influenza A virus X31 (H3N2) as compared to monovalent sialic acid.[10]  
In the present study, we systematically explored trivalent sialosides with different OEG lengths using two differently 
functionalizable core structure with either (i) an adamantane core, and (ii) a commercially available tris i.e. 4-
(((benzyloxy)carbonyl)amino)-4-(2-carboxyethly)heptanedioic acid core. Due to a restricted degree of rotational freedom 
of the anchorage points on the different scaffolds, adamantane can be considered to be more rigid compared to tris. 
Here we present the synthesis and comparative analysis of rigid and flexible core based trivalent sialosides with 
different spacer lengths for binding to IAV-X31 (subtype Aichi) using microscale thermophoresis (MST) and 
hemagglutination inhibition (HAI) assays. Despite the challenges associated with the spacer length optimization, we 
could identify an inhibitor against X31 with a HAI value in the micromolar range, thus being approximately 3000-fold 
more potent compared to monomeric SA. The present study reveals insights into the scaffold selection and spacer 
length optimization and emphasizes their relevance for the design of trivalent HA binder. 
Results and Discussion 
Based on the crystal structure of a single HA trimer (pdb: 1hgg), we determined the projected distance between the 
receptor binding sites, and the trimer midpoint of 2.6 nm. The binding site is found about 0.9 nm below the top of the HA 
surface, which leads to an effective distance of 3.5 nm between the receptor binding sites and the HA midpoint. The 
part of the tripod has a length of approximately 1.2 nm. Hence the OEG- spacer has to bridge a distance of 
approximately 2 nm. The length distribution of flexible OEG chains that we obtained from our previous MD 
simulations,[11] suggested that the OEG-linker must consist of at least 6-14 ethylene glycol units to span the distance 
between the ligand core and the binding sites (c.f. Supporting Information) 
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Figure 1. a) Top and b) side view of the HA -region (pdb: 1hgg). Bound sialic acid is highlighted in green. 
Synthesis of adamantane based trivalent and bivalent sialosides  
Heterobifunctional oligoethylene glycols,[12] tris(2-carboxymethyl)aminoadamantane amine,[13] bis(2-
carboxymethyl)aminoadamantaneamine and cbz-protected adamantane triacid,[14] and diacid[15] were prepared as 
reported in literature. SA-conjugated trivalent derivative with only an ethylene spacer 4 was prepared by using amide 
coupling with an ethanolamine sialic acid derivative 3 (Scheme 1). While reactions of adamantane triacid were less 
efficient when done by direct amide coupling of bigger length EG14 spacer. Therefore, coupling of cbz-protected 
adamantane triacid 1 with propargylamine provided an easy way to couple heterobifunctional oligoethylene glycols by a 
click chemistry approach. The addition of extra triazole units by amide bonds provided the limited flexibility and 
decreased the length requirements of a flexible OEG spacer. Heterobifunctional azido-tosylated EG6 and EG14 were 
synthesized as short and long OEG spacers to achieve the predicted OEG requirements. The prop-2-ynyl α-
thiosialoside was synthesized using procedure reported by Roy et al[16] and a slightly modified procedure of Ogura et 
al.[17] The prop-2-ynyl α-thiosialoside was conjugated by click chemistry to trivalent adamantane derivatives 6 and 7 
(Scheme 2). For the preparation of divalent adamantane sialoside, a heterobifunctional EG6 spacer bearing azide and 
sialic acid residues 13 was synthesized and coupled to divalent propargylated adamantane 12. The adamantane 
divalent sialoside was prepared to study the dependency of affinity on the presence of 2 vs 3 sialic acid valencies on the 
rigid core (Scheme 3). 
 
Scheme 1. Synthesis of adamantane core trivalent sialoside with an EG1 spacer. 
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Scheme 2. Synthesis of adamantane core trivalent sialosides with EG6 and EG14 spacers. 
 
 





Synthesis of Tris-based trivalent sialosides  
4-(((benzyloxy)carbonyl)amino)-4-(2-carboxyethly)heptanedioic acid 16 was prepared according to literature procedures 
from di-tert-butyl 4-amino-4-(3-(tert-butoxy)-3-oxopropyl)heptanedioate 15[17] followed by coupling with propargylamine 
to produce tripropagylated derivative 19. The triazido derivatives cbzTris(EG4N3)3 22 and cbzTris(EGN3)3 20 were 
prepared in two consecutive steps by conjugating heterobifunctional azido-tosyl EG4 and EG1 units followed by in situ 
azidation (Scheme 5). Prop-2-ynyl α-thiosialoside was then clicked in a similar fashion as done before to afford the final 
trivalent sialosides with a flexible core 21 and 23. Heterobifunctional amino-azido EG7 was easily obtained from 
Polypure which was then coupled with 4-(((benzyloxy)carbonyl)amino)-4-(2-carboxyethly)heptanedioic acid 16 using 
amide coupling (Scheme 4). Prop-2-ynyl α-thiosialoside was clicked with cbzTris(EG7N3)3 17 as described before to 
afford cbzTris(EG7SA)3 18.   
 
Scheme 4. Synthesis of Tris core trivalent sialoside with EG7 spacer. 
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Scheme 5. Synthesis of Tris core trivalent sialosides with an EG1 and EG4 spacer. 
Influenza virus binding studies 
Binding of all synthesized sialosides and control molecules to influenza A virus X31 was studied first by an 
hemagglutination inhibition assay. Unfunctionalized core molecules (1 and 16), and core molecules carrying only OEG 
spacers (24 and 17) did not show any significant hemagglutination binding inhibition through-out the tested 
concentration range (Figure 2). Among the adamantane based compounds, only the trivalent sialoside with EG6 spacer 
length, i.e., cbzAd(EG6SA)3 8 showed inhibition in the micromolar range. This suggests a divalent interaction, which was 
subsequently validated by synthesizing a divalent sialoside cbzAd(EG6SA)2 14. Binding inhibition values for both 
cbzAd(EG6SA)3 8  and divalent cbzAd(EG6SA)2 14 were in the micromolar range, i.e., 30 and 100 µM, respectively. The 
values based on SA are 100 and 200 µM, respectively. The slight difference between both values can be rationalized by 
the cooperativity factor which is discussed in the next section.  
Next, microscale thermophoresis (MST) was applied to determine the affinity constants of all constructs using 
rhodamine (R18) labeled intact X31 virus. The apparent Kd,app values for both trivalent and divalent rigid core-based 
adamantane sialosides 8 and 14 were almost in the same micromolar range, i.e., 58 and 71 µM respectively. Other 
adamantane based constructs did not show any affinity for the virus which is in agreement with the results from the HAI 
assay. 
The flexible Tris-based core sialosides showed HAI values only in the millimolar range, 6.67 mM was lowest for the one 
with EG4 spacer, i.e., cbzTris(EG4SA)3 23. In contrast, the affinity constant values KiHAI for the Tris core trivalent 
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sialosides measured by MST were in the micromolar range. cbzTris(EG4SA)3 23 showed enhanced affinity towards 
virus particles with apparent Kd,app around 16 µM. A shorter or longer spacer caused around 10 times lower affinity. The 
disagreement between the results of HAI and MST measurements might be due to additional non-specific interactions 
of the compounds with the red blood cells or viral surface at sites other than the sialic acid binding pockets of HA.  
Both cores (Ad and Tris) are similar in size. However, the dissociation constant of inhibitor 8 and 23, which have similar 
spacer lengths but different cores, differ significantly. We attribute this difference to the flexibility of the inhibitor cores. A 
binding event is always associated with a restriction of conformational degrees of freedom, which weakens the binding 
affinity. In case of the more rigid Ad-core, this conformational restriction is less pronounced compared to the more 
flexible Tris-core, which leads to a stronger binding affinity for Ad-based inhibitors. 
Table 1: Summary of hemagglutination inhibition values (KiHAI) and apparent dissociation constants (Kd,app) as determined by microscale 
thermophoresis (MST). Data from the HAI are given in respect to SA or tripod concentration. For Kd,app values the mean (N≥4) and SEM are 
given. 
Compound KiHAI (mM) SA KiHAI (mM) tripod 
Kd,app (µM) 
tripod 
2,6-sialyl lactose 100 - ND 
cbzAd(EG1SA)3 4 >20 >6.7 no binding 
cbzAd(EG6SA)3 8 0.10 0.03 58±15 
cbzAd(EG14SA)3 9 >15 >5 no binding 
cbzAd(EG6SA)2 14 0.20 0.10 71±11 
cbzAd(COOH)3(Control) 1 no inhibition >10 no binding 
cbzAd(EG6OH)3(Control) 24 no inhibition - no binding 
cbzTris(EG1SA)3 21 >20 >6.7 169±21 
cbzTris(EG4SA)3 23 20 6.7 16±4 
cbzTris(EG7SA)3 18 >50 >16.7 124±21 
cbzTris(COOH)3(Control) 16 no inhibition 
- 
no binding 






Figure 2. Microscale thermophoresis measurements with intact R18 labeled X31 virus against a) different adamantane-based or b) Tris-based 
constructs. The change in fluorescence intensity during thermophoresis is shown as a function of the construct’s concentration. Data points are 
one-sited fit. Error bars indicate the SEM (N≥4). 
 
Model for trivalent vs. divalent binding 
The HA inhibition measurements reveal a binding affinity of the trivalent inhibitor 8 that is by about a factor of three 
stronger than the binding affinity of the divalent inhibitor 14.To further investigate the size range in which trivalent 
inhibitors have the potential to outperform their divalent counterparts, we theoretically determined the ratio of the 
trivalent and divalent dissociation constant in dependence of the average spacer length. The dissociation constant, Kn, 






where each binding moiety, i.e. each bound sialic acid, contributes with Kmono, the monovalent dissociation constant, to 
the multivalent dissociation constant. We set Kmono, = 2.5 mM[19] for the monovalent sialic acid. The angular restriction 
factor ⍵ accounts for the reduced rotational degrees of freedom due to steric repulsion between the sialic acid and the 
OEG spacer. This parameter ⍵ describes the angular space available to each sialic acid compared to an unbound 
monovalent sialic acid unit. We assumed a value of ⍵=0.03, which was found for pentavalent inhibitors against cholera 
toxin and heptavalent inhibitors against the anthrax receptor.[18] The impact of the inhibitor scaffold on the multivalent 
dissociation constant is quantified by the cooperativity factor Cn, which describes the probability that all n sialic acid 
units are simultaneously bound to the HA receptor. The cooperativity factor accounts for the ligand conformation as well 
as the number of binding permutations. For both the trivalent as well as the divalent ligand there are six equivalent 
binding permutations by which the ligands can bind to a trivalent receptor. For the divalent inhibitor, Cn is equivalent to 
the effective concentration. A detailed discussion of the influence of inhibitor core size and spacer length on the 
cooperativity factor is presented in the Supporting Information. According to Eq. 1 the ratio between the dissociation 







which is shown in Figure 3 depending on the average spacer length rete. Over a wide range of spacer lengths, the 
dissociation constant of di- and trivalent inhibitors differ by less than one order of magnitude. While for very short 
spacers, divalent inhibitors bind stronger than trivalent inhibitors, in the size range of spacer length that is optimal for HA 
binding, i.e., for spacers with a length of around 1.4 nm, the binding affinity of trivalent inhibitors surpasses the divalent 
inhibitors, due to a favorable binding cooperativity.   
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Figure 3. Trivalent vs. divalent binding: The ratio of the trivalent dissociation constant K3 and the divalent dissociation constant K2, according to 
Eq. 2. The distance between 1.4 nm and 2.3 nm that has to be bridged by the inhibitor spacer to reach HA binding pocket, is indicated by a 
dashed vertical line.     
Computer simulation studies 
To answer the question why only compound 8 exhibited a significant affinity, we set up molecular dynamics simulations 
of the monovalent counterparts of compounds 8 and 9. This simulation protocol was chosen in order to minimize 
computational costs. Still, we were able to determine the behavior of the entire inhibitor, since the extensions of the 
individual OEG spacers are independent of each other. To trace the conformational behavior of the simulated ligands, 
we measured the distance distributions for several atom pairs as indicated in Figure 4A. First, we were interested if 
addition of the OEG spacer influenced the conformational behavior of the adamantane core. As presented in Figure 4B, 
the C8-N5 atom pair distance distributions of both investigated molecules overlapped and were mostly located in the 
range of 0.7 nm to 0.9 nm. This finding was not surprising, as the planarity of the amide bond and adjacent triazole ring 
provided the limited flexibility of this building block. In Figures 4C and 4D respectively, the distribution of the distance 
between outermost OEG oxygens, of and the distance between the adamantane core and the sialic acid is shown. Both 
distributions overlap, but the C8-S1 distribution was much narrower, which suggests that the sialic acid and the inhibitor 
core were in close contact without a receptor, i.e. the binding pocket. Therefore, we investigated the formation of the 
intramolecular hydrogen bonds between all the pairs of hydrogen bond donors and acceptors. Our analysis revealed 
that sialic acid remained free to potentially interact with the respective binding site of HA. In both simulated systems, the 
bonded atom pair N2-H20 was the most dominant hydrogen bond donor. It holds the OEG spacer and imidazole ring 
adjacent to the sialic acid in proximity to the adamantane core through the formation of several transient hydrogen 
bonds. In the case of compound 8, N2-H20 donor participated in the intramolecular hydrogen bonding for 34.5% of the 
simulation time, whereas it acted for compound 9 for the half of the simulation time. These findings would suggest that 
these two compounds should have bound to HA with almost similar affinity. Intuitively one notices from Figures 4E and 
4G the increase in the length of OEG spacer is correlated with the increase in the size of the respective OEG coil. To 
quantify the size of OEG coils, we used the radius of gyration as a measure. As shown in Figure 4G, the size of OEG 
coils of compound 9 is indeed larger compared to compound 8. If we now consider that all three OEG arms adopted the 
OEG-coil conformation, then the whole molecule would have been in a rather globular /compact conformation resulting 
in sterical repulsion from the receptor. Having the larger overall size of the OEG-coils, long spacer inhibitor 9 would 
repel more often from the surface of the receptor, thus the probability for the binding event is reduced compared to short 
spacer inhibitor 8.  
Consequently, this suggests that compound 8 unfolds from the coil-like structure easier than compound 9, which might 





Figure 4. (A) Pymol representations of the monovalent counterparts of compound 10 (left panel) and compound 11 (right panel). The atoms used 
to characterize the conformational dynamics of the ligands are marked according to the Acpype parametrization. (B) The distance distribution of 
the C8-N5 atom pair capturing the dynamics of the rigid part of the ligands. (C)  The distance distribution of the C8-S1 atom pair capturing the 
distance between the rigid core and sialic acid. (D) The distance distribution of the outermost oxygen atoms of OEG spacers. (E) Pymol 
representation of the most stable intramolecular hydrogen bond of compound 8. (F) Pymol representation of the most stable intramolecular 
hydrogen bond of compound 9. (G) Distribution of the radius of gyration compounds 8 and 9.  
Conclusion 
We have presented a quantitative comparison of the rigid and flexible core trivalent sialosides for influenza virus 
inhibition. The rigid adamantane core trivalent sialoside with hexamethylene glycol spacer is the most potent candidate 
against IAV/X31, showing an inhibitory constant in the micromolar range. On the contrary, no binding was observed with 
a longer OEG spacer, which is consistent with the simulation data that suggests increased conformational penalties 
when the OEG length is increased from EG6 to EG14. We also observed that trivalent cbzAd(EG6SA)3 4 (Ki = 30 µM) 
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was slightly more potent than the divalent cbzAd(EG6SA)2 14 (Ki = 100 µM) in the HAI assay, which could be assigned 
to a somewhat higher rebinding probability for the trivalent sialoside. However, both binding constants indicate a 
bivalent binding between ligand and receptor. For the flexible tris core, higher entropic penalties are associated and 
interfere with binding to the receptors.. Flexible Tris core based systems did not show any potent inhibitions in the HAI 
assay. The observed micromolar range affinity constant values in MST for the Tris core sialosides might be assigned to 
an interaction other than HA with the virus particles. Following, non-specific interaction of Tris-based compounds with 
cell membranes or binding to virus structures other than HA needs to be further investigated. Overall, our findings show 
that optimizing a significantly active trivalent sialoside with a non-toxic and structurally simple spacer like OEG is a 
challenging task because of high conformational entropic penalties and the chance of intramolecular hydrogen bonding 
with the spacer groups on the core itself. Nevertheless, we could design an adamantane-based trivalent sialoside which 
was significantly more active in the HAI assay compared to monovalent SA or other adamantane derivatives used in 
this study. Trivalent cluster units, such as cbzAd(EG6SA)3, could be further used for a multimeric presentation on larger 
scaffolds to achieve even better inhibition constants against the influenza A virus. 
 
Experimental Section 
Materials and Methods 
Synthesis 
All reagents and solvents were purchased from commercial suppliers and used without further purification. Analytical 
grade PEG600 (~EG14OH), hexa-, tetraethylene glycol, and azido-amino EG7 were purchased from Fischer Chemical, 
Sigma Aldrich, Acros Organic, and Polypure respectively. Reactions requiring dry or oxygen-free conditions were 
carried out under argon in Schlenk glassware. 1H and 13C NMR spectra were recorded on Bruker AMX 500 (500 and 
125 MHz for 1H and 13C NMR, respectively) and Delta Joel Eclipse 700 (700 and 175 MHz for 1H and 13C NMR, 
respectively) spectrometer at 25 oC and calibrated by using the deuterated solvent peak. Infrared (IR) spectra were 
recorded with a Nicolet AVATAR 320 FT-IR 5 SXC (Thermo Fisher Scientific, Waltham, MA, USA) with a DTGS 
detector from 4000 to 650 cm−1. A TSQ 7000 (Finnigan Mat) instrument was used for ESI measurements and a JEOL 
JMS-SX-102A spectrometer was used for the high-resolution mass spectra. Naturally occurring sialic acids constitute a 
family of more than 50 structurally distinct nine-carbon 3-deoxy-ulosonic acids, the most widespread derivative being 5-
N-acetyl-neuraminic acid (Neu5Ac) was used as starting material for the preparation of prop-2-ynyl α-thiosialoside. We 
used the abbreviation of sialic acid (SA) for Neu5Ac. Similarly ‘Tris’ was used as an abbreviation for the commercially 




X31 virus (influenza strain A/Aichi/2/68 H3N2) was harvested from allantoic fluid of embryonated chicken eggs. Virus 
isolates were clarified upon low speed centrifugation (300 x g, 10 min). For binding (inhibition) experiments clarified 
allantoic fluid was further concentrated by ultracentrifugation (100,000 x g, 1 h). 
Synthesis and characterization 
cbzAd(CH2CH2-NHS)3 2 
 
 cbzAd(CH2CH2COOH)3 1[17] (510 mg,1 mmol), EDC·HCl (868 mg, 4.5 mmol) and NHS-OH (520 mg, 4.5 mmol) were 
dissolved in 20 mL abs. DMF and stirred for 12 h at rt. The solvent was removed in vacuo and the residue was 
dissolved in 50 mL EtOAc. The solution was washed with water (3 x 50 mL), dried over Na2SO4, and filtered. The 
solvent was removed in vacuo and the residue recrystallized from PrOH to give the title compound 2 (729 mg, 92 %) as 
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a colorless solid. 1H NMR (600 MHz, CDCl3): δ (ppm) = 7.39 – 7.29 (m, 5H, aryl H), 5.04 (s, 2H, benzyl H), 4.87 (s, 1H, -
NH-), 2.82 (br s, 12H, 9-H), 2.60 (t, 6H, 3J = 7.6 Hz, 6-H), 1.70 (t, 6H, 3J = 7.6 Hz, 5-H), 1.64 (s, 6H, 2-H), 1.22 (d, 3H, 2J 
= 12.0 Hz, 4-Ha), 1.14 (d, 3H, 2J = 12.0 Hz, 4-He); 13C NMR (150 MHz, CDCl3): δ (ppm) = 169.3, 169.2, 154.8, 136.9, 
128.7, 128.2, 128.2, 66.3, 52.7, 44.8, 44.8, 36.8, 35.2, 25.7, 25.3; IR (film): ν = 2974, 2860, 1724, 1460, 1070, 910 cm-1; 




O- benzyloxycarbonylaminoethoxy sialic acid 3 (166 mg, 0.33 mmol) was dissolved in 5 ml H2O/MeOH (v/v = 1/4) 
and treated with LiOH (26 mg, 1.10 mmol). The solution was stirred at rt for 2 h and neutralized with Amberlite IR-120. 
After filtration, the solution was freeze dried and the residue was dissolved in 20 mL MeOH/H2O (v:v = 1:1). The solution 
was treated with 10 mg Pd/C under H2-atmosphere (balloon) and stirred for 24 h at rt. After filtration, the solvent was 
removed in vacuo and the residue was dissolved in abs. DMSO and treated with NEt3 (50 µL, 0.36 mmol). To this 
solution, NHS-ester 2 (75 mg, 0.09 mmol) was added and the mixture was stirred for 48 h at rt. The solvent was 
removed in vacuo and the crude product was purified by column chromatography on RP-18 silica (H2O/MeCN 1:0 → 
0:1). The title compound 4 (37 mg, 35 %) was obtained as a colorless solid. 1H NMR (600 MHz, D2O): δ (ppm) = 7.47 – 
7.37 (m, 5H, aryl H), 5.07 (s, 2H, benzyl H), 3.89 – 3.78 (m, 12H, 18-H, 16-H, 14-H), 3.72 – 3.66 (m, 6H, 13-H, 17-H), 
3.64 (td, 3H, 2J = 10.1 Hz, 3J = 5.1 Hz, 9-Ha), 3.58 (br d, 3H, 3J = 9.2 Hz, 15-H), 3.51 (td, 3H, 2J = 10.1 Hz, 3J = 5.1 Hz, 
9-Ha), 3.36 – 3.31 (m, 6H, 8-H), 2.73 (dd, 3H, 2J = 12.3 Hz, 3J = 4.8 Hz, 12-He), 2.22 (br s, 6H, 6-H), 2.03 (s, 9H, -
NHCOCH3), 1.68 (dd, 3H, 2J = 12.3 Hz, 3J = 12.3 Hz, 12-Ha), 1.54 (s, 6H, 2-H), 1.49 (br s, 6H, 5-H), 1.17 (d, 3H, 2J = 
12.0 Hz, 4-Ha), 1.11 (d, 3H, 2J = 12.0 Hz, 4-Hb); 13C NMR (150 MHz, D2O): δ (ppm) = 177.8, 175.1, 173.6, 136.7, 
128.8, 128.2, 127.6, 100.5, 72.6, 71.6, 68.2, 68.2, 66.3, 62.64, 62.61, 52.9, 51.9, 44.3, 44.1, 40.2, 39.4, 38.4, 34.6, 
30.0, 22.0; IR (film): ν = 2920, 1751, 1670, 1527, 1369, 1226, 1076, 1039, 848 cm-1; HRMS (ESI): m/z calcd. for 
C66H101N7O32: 1504.6564 [M+H+], found 1504.6535. 
 
Synthesis of the compound cbzAd(propargyl)3 5 
cbz-Adamantane triacid 1 (0.7 g, 1.4 mmol) was dissolved in dry DMF (100 mL) and cooled to 0 oC (ice bath). DIPEA 
(0.9 mL, 5.3 mmol) was added to the reaction mixture and stirred for 5 min followed by addition of EDC.HCl (1.0 g, 5.3 
mmol) and HOBt (0.7 g, 5.3 mmol). The reaction mixture was stirred for 30 min. Then propargyl amine (0.3 mL, 5.3 
mmol) was added and stirred for 72 h at room temperature. DMF was removed and the residue was dissolved in ethyl 
acetate (250 mL) and washed with 1 M HCl (3 × 100 mL), water (100 mL), and brine (2 × 50 mL). The organic phase 
was dried over Na2SO4, and the solvent was removed under reduced pressure. The resulting crude product was purified 
by flash chromatography on silica gel (CHCl3/methanol) to afford the propargylated product 5 (453.68 mg, 53 %).1H 
NMR (400 MHz, CD3OD): δ (ppm) = 7.34-7.26 (m, 5H, aryl H), 5.01 (s, 2H, benzyl H), 3.93 (d, 6H, 4J = 4.0 Hz, -
NHCOCH2CCH), 2.57 (t, 3H, 4J = 4.0 Hz, -NHCOCH2CCH), 2.17 (t, 6H, 3J = 4.0 Hz, AdCH2CH2CONH-), 1.58 (s, 6H, 
AdH), 1.49 (t, 6H, 3J = 8.0 Hz, AdCH2CH2CONH-), 1.19-1.09 (m, 6H, AdH); 13C NMR (100 MHz, CD3OD): δ (ppm) = 
176.2, 153.4, 138.6, 129.4, 128.9, 128.7, 80.7, 72.1, 53.7, 46.3, 45.9, 39.7, 36.1, 30.8, 29.4; IR (film): ν = 3282, 2913, 
1645, 1529, 1454, 1420, 1385, 1353, 1307, 1235, 1024 cm−1; HRMS (ESI) = m/z calcd. for C36H44N4O5 : 635.3209 
[M+Na+]; found: 635.3200.  
Synthesis of the compound cbzAd(EG6N3)3 6 and cbzAd(EG14N3)3 7 
The cbz protected adamantane (propargyl)3 5 (50.0 mg, 0.081 mmol) and N3EG6OTs (Scheme S3) (188.0 mg, 0.041 
mmol) was dissolved in DMF (10mL). CuSO4.5H2O (12.2 mg, 0.048 mmol) was dissolved in 0.2 mL of H2O and added to 
the solution of sodium ascorbate (97.2 mg, 0.48 mmol) in 0.4 mL H2O. The resultant solution of salts in water was 
added drop wise to the solution containing cbzAd(propargyl)3 5 and N3EG6OTs.  The reaction mixture was degassed 
with argon for 10 minutes and then allowed to stir at room temperature for 48 h. The completion of reaction was 
monitored by checking TLC and ESI. HRMS(ESI) = m/z calcd. for C93H137N13O26S3: 2019.8739 [M+Na+]; found: 
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2019.8884 to ensure the reaction completion. It was followed by in situ azidation with NaN3 (31.8 mg, 0.489 mmol), at 
70 oC for 24 h. The stirring was stopped, and solvent was removed under reduced pressure. Reaction mixture was first 
filtered through celite and washed with CHCl3 to remove excess of DMF. The organic solvent was evaporated. The 
crude product was purified by flash column chromatography on silica gel (CHCl3/MeOH) to afford the pure product as 
colorless oil (65.0 mg, 50 %). 
cbzAd(EG6N3)3 6 
1H NMR (500 MHz, CDCl3): δ (ppm)= 7.69 (s, 3H, -C=CH-), 7.32-7.28 (br m, 4H, aryl H), 6.92 (s, 1H, aryl H ), 4.96 (s, 
2H, benzyl H), 4.47 (t, 6H, J = 10 Hz, -TrzCH2CH2O-), 4.44 (d, 6H, J = 10 Hz, -NHCH2Trz-),  3.81 (t, 6H, J = 10 Hz, -
TrzCH2CH2O-), 3.64 - 3.57 (m, 66 H, -OCH2CH2N3, EG spacer), 3.35 (t, 6H, J = 10 Hz, -OCH2CH2N3), 2.08 (t, 6H, J = 
10 Hz, AdCH2CH2CONH-), 1.47-1.44 (br m, 12H, AdH and AdCH2CH2CONH-), 1.06-0.94 (br m, 6H, AdH); 13C NMR 
(125 MHz, CDCl3): δ (ppm) = 173.4, 154.4, 144.6, 136.7, 128.5, 128.0, 123.4, 70.5, 70.0, 69.4, 65.9, 52.7, 50.6, 50.2, 
45.1, 38.0, 34.9, 30.1, 29.6, 22.8; IR (film): ν = 3301, 2906, 2360, 2105, 1715, 1654, 1540, 1455, 1349, 1302, 1242, 
1117, 940, 736 cm−1; HRMS (ESI) = m/z calcd. for C72H116N22O20: 1631.8634 [M+Na+]; found: 1631.8717. 
cbzAd(EG14N3)3 7 
Synthesis was carried out by the above-reported procedure. The crude product was purified by dialysis with MWCO 
2kDa in CHCl3 to afford the pure product as colorless oil (125.77 mg, 58.5 %), 1H NMR (500 MHz, CD3OD-CD2Cl2): δ 
(ppm) = 7.75 (s, 3H, -C=CH-), 7.26 (br s, 4H, aryl H ), 7.13 (s, 1H, aryl H ), 4.94 (s, 2H, benzyl H), 4.90-4.47 (br m, 12H, 
-TrzCH2CH2O- and -NHCH2Trz-),  4.35 (s, 6H, -TrzCH2CH2O-), 3.81 (s, 6H, -OCH2CH2N3), 3.58-3.33 (m, 156 H, -
OCH2CH2N3, EG spacer), 1.49-1.43 (m, 12H, AdH and AdCH2CH2CONH-), 1.10-1.01 (br m, 6H, AdH); 13C NMR (125 
MHz, CDCl3): δ (ppm) = 173.5, 154.5, 144.7, 136.6, 128.6, 128.1, 123.5, 70.6, 70.1, 69.4, 66.0, 52.8, 50.7, 50.3, 45.3, 
38.1, 35.0, 34.1, 29.7, 22.9; IR (film): ν = 3318, 2910, 2868, 2103, 1769, 1717, 1651, 1534, 1455, 1349, 1283, 1240, 
1113, 1035, 992, 932, 841, 777 cm−1; HRMS (ESI) = m/z calcd. for C120H212N22O44: 2705.4698 [M+K+]; found: 
2705.4340. 
Synthesis of the compound cbzAd(EG6SA)3 8 and cbzAd(EG14SA)3 9 
cbzAd(EG6SA)3 8 
cbzAd(EG6N3)3 6 (0.05 g, 0.03 mmol) and prop-2-ynyl α-thiosialoside (0.06 g, 0.11 mmol) was dissolved in DMF (5 mL). 
The CuSO4.5H2O (0.77 mg, 0.003 mmol) was dissolved in 0.2 mL of H2O and added to the solution of sodium ascorbate 
(6.2 mg, 0.03 mmol) in 0.4 mL H2O. The resultant solution of salts in water was added drop wise to the solution 
containing cbzAd(EG6N3)3 6 and prop-2-ynyl α-thiosialoside. The reaction mixture was degassed with argon for 10 
minutes and then allowed to stir at room temperature for 48 h. The completion of reaction was monitored by IR for the 
disappearance of the N3 frequency at 2100 cm-1. After the reaction completion, DMF was evaporated over a rota-vapor. 
Then 2M NaOH (5 mL) solution was added to the left-over residue and stirred for 2 h at room temperature. The solution 
was dialyzed against water for 3 days using dialysis membrane with MWCO 2 kDa to afford the pure product as white 
solid (70.56 mg, 84 %). 1H NMR (700 MHz, D2O): δ (ppm) = 7.87 (s, 3H, -C=CH-), 7.26 (br s, 5H, aryl H ), 4.91 (s, 2H, 
benzyl H), 4.49 (br s, 12H, -TrzCH2CH2O- and -OCH2CH2Trz-), 4.34 (br s, 6H, -NHCH2Trz-),  3.95 - 3.48 [m, 87H, -
TrzCH2CH2O-, -OCH2CH2Trz-, SA (8-H, NH, 7-H, 4-H, 9-H, 5-H, 6-H), SCH2C=C, EG spacer], 2.72 (d, 3H, J = 7 Hz, SA 
H-3e), 2.10 (br s, 6H, AdCH2CH2CONH-), 1.94 (s, 3H, SA NHAc), 1.69 (s, 3H, SA H-3a), 1.35 (br s, 12H, AdH and 
AdCH2CH2CONH-), 0.94 (br s, 6H, AdH); 13C NMR (175 MHz, D2O): δ (ppm) = 177.0 175.1, 156.0, 145.0, 136.6, 128.7, 
128.2, 127.6, 124.8, 124.5, 74.8, 71.7, 69.5, 68.7, 68.7, 68.5, 68.1, 65.9, 62.5, 52.6, 51.7, 50.0, 44.3, 44.2, 40.6, 38.0, 
34.6, 34.4, 29.9, 23.5, 22.0; IR (film): ν = 3268, 2915, 1644, 1608, 1550, 1372, 1133, 1028, 951, 834 cm−1; HRMS (ESI) 




Synthesis was carried out by the above-reported procedure. The crude product was purified by dialysis with MWCO 
2kDa in CHCl3 to afford the pure product as colorless oil (69.83 mg, 62 %). 1H NMR (700 MHz, D2O): δ (ppm) = 7.97 (s, 
3H, -C=CH-), 7.36 (br s, 5H, aryl H ), 5.02 (s, 2H, benzyl H), 4.57 (br s, 12H, -TrzCH2CH2O- and -OCH2CH2Trz-), 4.41 
(br s, 6H, -NHCH2Trz-), 4.04 - 3.52 [m, 180H, -TrzCH2CH2O-, -OCH2CH2Trz-, SA (8-H, 7-H, 4-H, 9-H, 5-H, 6-H), 
SCH2C=C, EG spacer], 2.79 (d, 3H, J = 7 Hz, SA H-3e), 2.18 - 2.16 (br m, 6H, AdCH2CH2CONH-), 2.01 (s, 3H, SA 
NHAc), 1.77 (s, 3H, SA H-3a), 1.44-142 (m, 12H, AdH and AdCH2CH2CONH-), 1.05-0.99 (br m, 6H, AdH); 13C NMR 
(175 MHz, D2O): δ (ppm) = 177.0, 175.1, 156.0, 145.0, 136.6, 128.7, 128.2, 127.6, 124.8, 124.5, 74.8, 71.7, 69.5, 68.7, 
68.7, 68.5, 68.1, 65.9, 62.5, 52.6, 51.7, 50.0, 44.3, 44.2, 40.6, 38.0, 34.6, 34.4, 29.9, 23.5, 22.0; m/z calcd. for 
C162H272N25NaO68S3: 3777.79 [M+Na+]; GPC (H2O): Mn = 4071 Da, Mw = 4756 kDa, PDI = 1.16; Elemental analysis: 
calcd. 51.79% C, 7.38% H, 9.32% N, 2.56% S, found. 51.62% C, 7.40% H, 9.29% N, 2.60% S. IR (film): ν = 3274, 2872, 
1607, 1549, 1454, 1350, 1245, 1080, 950, 892, 834 cm−1. 
Synthesis of the compound cbzAd(COOH)2 11 
Bis(2-carboxyethyl) aminoadamantane 10 (2 g, 6.78 mmol) was dissolved in dioxane (30 mL) followed by addition of 
aqueous NaHCO3 (850 mg, 10.12 mmol, 30 mL) solution. NaOH (2M) was added to the reaction mixture to achieve the 
pH of 9 and the reaction mixture was cooled to 0 oC (ice bath). Benzyl chloroformate (1.73 mL, 12.10 mmol) was added 
dropwise to the stirred solution. Stirring was continued at room temperature overnight. The reaction mixture was 
washed three times with CH2Cl2 (30 mL) and three times with EtOAc (30 mL), acidified to pH 1, and extracted six times 
with EtOAc. The combined organic layers were dried over Na2SO4, filtered, and concentrated to give the intermediate 
cbz-protected diacid (1.78 g, 62 %). 1H NMR (500 MHz, CDCl3): δ (ppm) = 7.37 - 7.31 (m, 5H, aryl H), 5.04 (s, 2H, 
benzyl H), 2.30 (t, 4H, 3J = 10 Hz, 9’-H), 2.20 (br t, 1H, 6’-H), 1.80 (br. s, 2H, 7’-H), 1.65 - 1.58 (m, 4H, 2’-H), 1.53 (t, 4H, 
3J = 10 Hz, 8’-H), 1.39 - 1.32 (m, 4H, 5’-H), 1.15 (br s, 2H, 4’-H); 13C NMR (125 MHz, CDCl3): δ (ppm) = 179.7, 128.6, 
128.2, 45.6, 40.4, 37.5, 34.7, 29.6, 28.1; IR (film): ν = 3032, 2915, 2850, 1704, 1587, 1497, 1454, 1392, 1341, 1302, 
1261, 1025, 941, 909, 823, 788 cm−1; HRMS (ESI) = m/z calcd. for C24H31NO6 : 452.2049 [M+Na+]; found: 452.2083.  
Synthesis of the compound cbzAd(propargyl)2 12 
cbz-protected diacid 11 (350 mg, 0.82 mmol) was dissolved in 15 mL dry DMF and cooled to 0 oC (ice bath). Then DCC 
(336 mg, 1.63 mmol) and N-hydroxysuccinimide (196 mg, 1.70 mmol) were added, and the reaction mixture was stirred 
at room temperature for 12 h. The completion of reaction was monitored by mass. Then propargyl amine (0.14 mL, 2.18 
mmol) was added and stirred for 72 h at rt. The solution was diluted with ethyl acetate (70 mL) and washed with 1M HCl 
(3 × 20 mL), water (40 mL), and brine (2 × 20 mL). The organic phase was dried over Na2SO4, and the solvent was 
removed under reduced pressure. The crude product was purified by column chromatography with a DCM/methanol 
mixture. (233.18 mg, 57 %). 1H NMR (700 MHz, CD3OD): δ (ppm) = 7.33 - 7.26 (m, 5H, aryl H), 4.99 (s, 2H, benzyl H), 
3.91 (d, 4H, 4J = 7 Hz, 11’-H), 2.34 (t, 2H, 4J = 7 Hz, 12’-H), 2.16 - 2.12 (m, 5H, 9’-H, 6’-H ), 1.79 (br s, 2H, 7’-H), 1.62 - 
1.55 (m, 4H, 2’-H), 1.48 - 1.44 (m, 4H, 8’-H), 1.39 - 1.29 (m, 4H, 5’-H); 1.14 (br s, 2H, 4’-H); 13C NMR (175 MHz, 
CD3OD): δ (ppm) = 175.5, 128.9, 128.5, 128.2, 80.0, 71.5, 52.6, 46.1, 45.8, 40.9, 39.2, 35.2, 30.3, 29.2; IR (film): ν = 
3288, 3060, 2910, 2847, 2358, 1701, 1646, 1536, 1454, 1420, 1343, 1301, 1235, 1138, 1113, 1045, 1031, 928, 736, 
697 cm−1; HRMS (ESI) = m/z calcd. for C30H37N3O4 : 527.2682 [M+1+Na+]; found: 527.2755. 
 
Synthesis of the compound SAEG6N3 13 
TsEG6N3 was synthesized from EG6 diol. The TsEG6N3  (500 mg, 1.08 mmol) and prop-2-ynyl α-thiosialoside (914 mg, 
1.68 mmol) were dissolved in DMF. CuSO4.5H2O (0.06 mg, 0.24 mmol) was dissolved in 0.2 mL of H2O and added to 
the solution of sodium ascorbate (511 mg, 2.57 mmol) in 0.4 mL H2O. The resultant solution of salts in water was added 
drop wise to the solution containing TsEG6N3 and prop-2-ynyl α-thiosialoside. The reaction mixture was degassed with 
argon for 10 minutes and then allowed to stir at 40 oC for 48 h. The completion of reaction was monitored by IR 
spectroscopy for the disappearance of azide peak. It was followed by in situ azidation with NaN3 (716 mg, 11.02 mmol), 
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at 70 oC for 24 h. The stirring was stopped, and solvent was removed under reduced pressure. The crude compound 
was purified by column chromatography to obtain the pure product SAEG6N3 13. (691.40 mg, 73 %). 1H NMR (500 
MHz, CD2Cl2): δ (ppm) =  7.66 (s, 1H, -C=CH-), 5.59 (m, 1H, 8-H), 5.43 - 5.39 (m, 1H, 7-H), 4.91 - 4.86 (m, 1H, 4-H), 
4.49 (t, J = 10 Hz, 2H, -TrzCH2CH2O-), 4.27 (dd, 1H,  2J = 10 Hz, 3J = 5 Hz, 9-Ha), 4.09 - 3.98 (m, 4H, 5-H, 9-He, -
SCH2C=CH-), 3.92 - 3.88 (m, 2H, 6-H, 5-H), 3.85 (t, 2H, -TrzCH2CH2O-), 3.71 ( s, 3H, -OCH3), 3.65 – 3.57 (m, 18H,  EG 
spacer), 3.36 (t, 2H, 3J = 5 Hz, -CH2CH2N3-),  2.74 (dd, 1H, 2J = 10 Hz, 3J = 5 Hz, 3-He), 2.14 (s, 3H, -OCOCH3),  2.11 
(s, 3H, -OCOCH3), 1.99 (s, 3H, -OCOCH3),  1.98 (s, 3H, -OCOCH3), 1.83 (s, 3H, -NHOCH3); 13C NMR (500 MHz, 
CD2Cl2): δ (ppm)= 171.0, 170.9, 170.5, 170.3, 168.7, 143.5, 123.9, 83.5, 74.5, 71.0, 71.0, 71.0, 70.9, 70.8, 70.3, 69.9, 
68.6, 67.9, 62.7, 53.5, 51.2, 50.7, 49.5, 38.1, 23.8, 23.4, 21.5, 21.1, 21.1, 21.0; IR (film): ν = 3274, 2869, 2103, 1736, 
1682, 1662, 1543, 1437, 1368, 1215, 1121, 1032, 946 cm−1; HRMS (ESI) = m/z calcd. for C35H55N7O17S : 900.3273 
[M+Na+]; found: 900.3270. 
Synthesis of the compound cbzAd(EG6SA)2  14 
The SAEG6N3 (174 mg, 0.20 mmol) and cbzAd(propargyl)2 12 (50 mg, 0.099 mmol) were dissolved in DMF, 
CuSO4.5H2O (9.9 mg, 0.03 mmol) was dissolved in 0.2 mL of H2O and added to the solution of sodium ascorbate (78 
mg, 0.39 mmol) in 0.4 mL H2O. The resultant solution of salts in water was added drop wise to the solution containing 
SAEG6N3 and cbzAd(propargyl)2. The reaction mixture was degassed with argon for 10 minutes and then allowed to stir 
at 40 oC for 48 h. The completion of reaction was monitored by IR spectroscopy for the disappearance of azide peak. 
The stirring was stopped, and solvent was removed under reduced pressure. 2M NaOH (20 mL) was added to the 
residue and stirred at room temperature for 12 h. The reaction mixture was dialyzed first against water and aqueous 
EDTA solution for 2 days and again using only water for 4 days. The aqueous solution obtained after dialysis was 
lyophilized to get the pure product cbzAd(EG6SA)2 14 (146.24 mg, 78 %). 1H NMR (700 MHz, D2O): δ (ppm) =  8.30 (br 
s, 4H, -C=CH-), 7.41 - 7.38 (m, 5H, aryl H), 5.04 (s, 2H, benzyl H), 4.65 - 4.62 (m, 4H, -TrzCH2CH2O- and -
OCH2CH2Trz-), 4.47 (br s, 4H, -NHCH2Trz-),  3.98 - 3.49 [m, 56H, -TrzCH2CH2O-, -OCH2CH2Trz-, SA (8-H, 7-H, 4-H, 9-
H, 5-H, 6-H), SCH2C=C, EG spacer], 2.89 (br s, 2H, SA H-3e), 2.28 (br s, 4H, AdCH2CH2CONH-), 2.13 (br s, 1H, 6’-H), 
2.04 (s, 6H, SA NHAc), 1.73 (br s, 2H, Ad 7’-H), 1.54 - 1.48 (m, 8H, Ad 2’-H, AdCH2CH2CONH-), 1.28 (br d, 4H, Ad 5’-
H), 1.11 (br s, 2H, Ad 4’-H); 13C NMR (175 MHz, D2O): δ (ppm) = 177.0, 174.9, 156.0, 136.9, 128.7, 128.2, 127.6, 74.8, 
71.8, 69.5, 68.5, 68.1, 62.4, 51.6, 50.4, 44.7, 40.6, 39.5, 38.3, 34.3, 29.2, 22.0; IR (film): ν = 3279, 2905, 2360, 1698, 
1614, 1551, 1428, 1349, 1235, 1109, 1023, 948, 890, 834 cm−1; HRMS (ESI) = m/z calcd. for C82H127N17O30S2: 
1915.8274 [M+Na+-1]; found: 1915.8152.  
Synthesis of the compound cbzTris(EG7N3)3 17 
cbz-protected triacid 16 (231 mg, 0.61 mmol) was dissolved in 15 mL of dry DMF and cooled to 0 oC (ice bath). Then 
triethylamine (0.35 mL, 2.51 mmol), EDC.HCl (493 mg, 2.57 mmol) and DMAP (169 mg, 1.38 mmol) were added, and 
the reaction mixture was stirred at 0 oC for 20 minutes. Then N3EG7NH2 (902 mg, 2.58 mmol) was added and stirred at 
room temperature for 72 h. The solution was diluted with ethyl acetate (70mL) and washed with 1 M HCl (3 × 20 mL), 
water (40 mL), and brine (2 × 20 mL). The organic phase was dried over Na2SO4, and the solvent was removed under 
reduced pressure. The crude product was purified by column chromatography with a DCM/methanol mixture to afford 
the pure cbzTris(EG7N3)3 17 (49.55 mg,  59 %). 1H NMR (500 MHz, DMSO-d6): δ (ppm) = 7.87 (t, 3J = 5 Hz, 3H,- 
NHCH2CH2-), 7.34 - 7.29 (m, 5H, aryl H ), 4.97 (s, 2H, benzyl H), 3.60 (t, 3J = 5 Hz, 6H, -NHCH2CH2-), 3.54 - 3.50 (m, 
60H, EG spacer), 3.39 (t, 3J = 5 Hz, 12H, -NHCH2CH2, -CH2CH2N3-), 3.18 - 3.16 (m, 6H, -CH2CH2N3-), 2.01 (t, 3J = 10 
Hz, 6H, - CH2CH2CONH-); 1.76 (br t, 6H, -CH2CH2CONH-); 13C NMR (125 MHz, DMSO-d6) : δ (ppm) = 172.1, 154.1, 
137.3, 128.3, 127.4, 69.7-69.1, 64.5, 56.1, 50.0, 30.3, 29.5; IR (film): ν = 3301, 2921, 2868, 2106, 1717, 1650, 1533, 
1455, 1348, 935, 746 cm−1; HRMS (ESI): m/z: calcd. for C60H107N13O23: 1400.7500 [M+Na+]; found 1400.7518. 
 
Synthesis of the compound cbzTris(EG7SA)3 18 
 16 
The prop-2-ynyl α-thiosialoside (154 mg, 0.42 mmol) and cbzTris(EG7N3)3 (100 mg, 0.07 mmol) were dissolved in DMF. 
CuSO4.5H2O (21 mg, 0.08 mmol) was dissolved in 0.2 mL of H2O and added to the solution of sodium ascorbate (217 
mg, 1.10 mmol) in 0.4 mL H2O. The resultant solution of salts in water was added drop wise to the solution containing 
prop-2-ynyl α-thiosialoside and cbzTris(EG7N3). The reaction mixture was degassed with argon for 10 minutes and then 
allowed to stir at 40 oC for 48 h. The completion of reaction was monitored by IR spectroscopy for the disappearance of 
azide peak. The stirring was stopped, and solvent was removed under reduced pressure 2M NaOH (20 mL) was added 
to the residue and stirred at room temperature for 12 h. The reaction mixture was dialyzed against water and aqueous 
EDTA solution. The aqueous solution obtained after dialysis was lyophilized to get the pure product cbzTris(EG7SA)3 
18. (125.85 mg, 73 %). 1H NMR (500 MHz, D2O) : δ (ppm) =  7.96 (s, 3H, -C=CH-), 7.42 - 7.36 (m, 5H, aryl H ), 5.03 (s, 
2H, benzyl H), 4.57 (br t, 6 H, -NHCH2CH2-), 4.02 - 3.49 (m, 99H, SA (8-H, NH, 7-H, 4-H, 9-H, 5-H, 6-H,) -SCH2C=C-, 
EG spacer), 3.33 (br t, 6H, -CH2CH2N3-), 2.78 (d, 3J = 10 Hz, 3H, SA 3-He), 2.19 (br t, 6H, - CH2CH2CONH-), 2.00 (s, 
9H, SA -NHCOCH3), 1.88 (m, 6H, -CH2CH2CONH-), 1.75 (t, 3H, 3J = 10 Hz, SA 3-Ha); 13C NMR (125 MHz, D2O) : δ 
(ppm) =  175.9, 128.9, 124.9, 74.9, 71.9, 69.7-69.6, 68.9, 68.8,68.7, 68.2, 62.67, 51.8, 50.2, 40.8, 39.2, 38.0 30.0, 23.9, 
23.8, 22.1; IR (film): ν = 3350, 2923, 1597, 1446, 1371, 1349, 1113, 1078, 986, 935, 903, 857 cm−1; HRMS (ESI): m/z: 
calcd. for C120H170N16O47S3: 2550.9982 [M+2Na++K+-1]; found 2550.9737. 
Synthesis of the compound cbzTris(propargyl)3 19 
cbz-protected triacid (950 mg, 2.49 mmol) was dissolved in 15 mL of dry DMF and cooled to 0 oC (ice bath). Then 
triethylamine (1.56 mL, 11.18 mmol), EDC.HCl (2.14 g, 11.16 mmol) and DMAP (638 mg, 5.22 mmol) were added, and 
the reaction mixture was stirred at 0 oC for 20 minutes. Then propargyl amine (0.717 mL,11.19 mmol) was added and 
stirred for 72 h at room temperature. The solution was diluted with ethyl acetate (70 mL) and washed with 1 M HCl (3 × 
20 mL), water (40 mL), and brine (2 × 20 mL). The organic phase was dried over Na2SO4, and the solvent was removed 
under reduced pressure. The crude product was purified by column chromatography with a DCM/methanol mixture. 
(732 mg, 60 %). 1H NMR (500 MHz, DMSO-d6) : δ (ppm) =  8.24 (t, 3J = 10 Hz, 3H, -NHCH2-), 7.36 - 7.29 (m, 5H, aryl 
H), 4.98 (s, 2H, benzyl H), 3.83 - 3.82 (m, 6H, -CH2CCH-), 3.08 (t, 5J = 5 Hz, 3H, -CH2CCH-), 2.03 (br t, 6H, -
CH2CH2CONH-), 1.77 (br t, 6H, -CH2CH2CONH-); 13C NMR (125 MHz, CDCl3) : δ (ppm) = 173.4, 155.2, 137.3, 128.9, 
128.4, 80.0, 71.9, 66.6, 57.5, 31.2, 30.7, 29.5; IR (film): ν = 3289, 3057, 2939, 1704, 1644, 1525, 1242, 1057, 1027, 
926, 732 cm−1; HRMS (ESI): m/z: calcd. for C27H32N4O5: 515.5658 [M+Na+]; 531.5397 [M+K+]; found: 512.2291, 
531.2023 respectively.  
Synthesis of the compound cbzTris(EG1N3)3 20 
The coupling of cbzTris(propargyl)3 (240 mg, 0.56 mmol) and azido ethyl tosylate (459 mg, 1.90 mmol) using copper 
assisted click reaction followed by azidation was performed like 22. (342.28 mg, 75 %). 1H NMR (500 MHz, DMSO-d6) : 
δ (ppm) = 7.83 (s, 3H, -C=CH-), 7.26 - 7.18 (m, 5H, aryl H), 4.92 (s, 2H, benzyl H), 4.46 (t, 3J = 5 Hz, 6H, -CH2CH2N3); 
4.34 (s, 6H, -CONHCH2-), 3.71 (t, 3J = 5 Hz, 6H, -CH2CH2N3); 2.14 (t, 6H, 3J = 5 Hz, -CH2CH2CONH-), 1.87 (t, 3J = 5 
Hz, 6H, -CH2CH2CONH-); 13C NMR (125 MHz, CD3OD) : δ (ppm) = 175.6, 156.6, 146.5, 129.4, 128.7, 124.8 66.9, 57.9 
51.7, 50.5, 35.6, 31.5, 31.0; IR (film): ν = 3287, 2925, 2107, 1712, 1678, 1529, 1455, 1240, 1061 cm−1; HRMS (ESI): 
m/z: calcd. for C33H44N22O5: 851.3763 [M+Na+]; found: 851.3788.  
Synthesis of the compound cbzTris(EG1SA)3 21 
The coupling of cbzTris(EG1N3)3 20 (32 mg, 0.04 mmol) and prop-2-ynyl α-thiosialoside (81.9 mg, 0.015 mmol) using 
copper-assisted click reaction and further deprotection was performed similarly to 18. (49.28 mg, 69 %). 1H NMR (500 
MHz, D2O) : δ (ppm) = 7.81 (br s, 3H, -C=CH-), 7.58 (br s, 3H, -C=CH-), 7.26-7.22 (m, 5H, aryl H), 4.89 (s, 2H, benzyl H 
), 4.22 - 3.43 [m, 42H SA (8-H, 7-H, 4-H, 9-H, 5-H, 6-H,) SCH2C=C, -CONHCH2-, ethylene spacer], 2.68 (br s, 3H, SA 3-
He), 2.13 (br s, 6H, -CH2CH2CONH-), 1.91 (s, 9H, SA -NHCOCH3), 1.80 (br s, 7H, -CH2CH2CONH-, SA 3-Ha); 13C NMR 
(125 MHz, D2O) : δ (ppm) = 175.7, 174.9, 136.7, 130.2, 129.4, 128.6, 128.1, 127.6, 74.8, 71.3, 68.0, 62.7, 51.6, 49.8, 
40.2, 34.5, 29.7, 22.0; IR (film): ν = 3317, 2971, 1647, 1557, 1374, 1364, 1032, 1013 cm−1; HRMS (ESI): m/z: calcd. for 
C75H107N25O29S3: 1960.6613 [M+2Na+-3]; found: 1960.6398. 
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Synthesis of the compound cbzTris(EG4N3)3 22 
The TsOEG4N3 was synthesized by reported procedure of Xuyi Yue et al.[12a] The cbzTris(propargyl)3 19 (200 mg, 0.47 
mmol) and TsOEG4N3 (590 mg, 1.58 mmol) were dissolved in DMF. CuSO4.5H2O (21 mg, 0.08 mmol) was dissolved in 
0.2 mL of H2O and added to the solution of sodium ascorbate (217 mg, 1.10 mmol) in 0.4 mL H2O. The resultant 
solution of salts in water was added drop wise to the solution containing TsOEG4N3 and cbzTris(popargyl)3. The 
reaction mixture was degassed with argon for 10 minutes and then allowed to stir at 40 oC for 48 h. The completion of 
reaction was monitored by TLC. It was followed by in situ azidation with NaN3 (308 mg, 4.74 mmol), at 70 oC for 24 h. 
The stirring was stopped, and solvent was removed under reduced pressure. The crude product was purified by column 
chromatography with a DCM/methanol mixture. (414.2 mg, 72 %). 1H NMR (700 MHz, MeOH-d4) δ: (ppm) = 7.90 (s, 
3H, -C=CH- ), 7.34 - 7.26 (m, 5 H, aryl H), 5.00 (s, 2H, benzyl H), 4.54 (t, 3J = 7 Hz, 6H, -TrzCH2CH2O-); 4.41 (s, 6H, -
CONHCH2-), 3.87 (t, 3J = 7 Hz, 6H, -TrzCH2CH2O-), 3.64 - 3.59 (m, 24H, EG spacer), 3.35 (t, 6H, 3J = 7 Hz, -
CH2CH2N3), 2.22 (br t, 6H, -CH2CH2CONH-), 1.95 (br t, 6H, -CH2CH2CONH-); 13C  NMR (125 MHz, CD3OD-d6) : δ 
(ppm) = 175.4, 156.5, 145.9, 138.4, 129.4 128.9, 128.7, 124.9, 171.5-71.0, 70.3, 66.8, 57.8, 51.7, 51.3, 35.7, 31.6, 31.0; 
IR (film): ν = 3301, 2921, 2868, 2106, 1717, 1650, 1533, 1455, 1244, 1098, 1058, 935 cm−1; HRMS (ESI): m/z: calcd. 
for C51H80N22O14: 1247.6122 [M+Na+]; found: 1247.6217. 
Synthesis of the compound cbzTris(EG4SA)3 23  
The coupling of cbzTris(EG4N3)3 22 (108 mg, 0.088 mmol) and prop-2-ynyl α-thiosialoside (187 mg, 0.34 mmol) using 
copper assisted click reaction and further deprotection was performed similarly to 18. (154 mg, 77 %). 1H NMR (500 
MHz, D2O) : δ (ppm) = 7.90 (s, 3H, -C=CH-), 7.86 (s, 3H, -C=CH-), 7.32 - 7.29 (m, 5H, aryl H), 4.96 (s, 2H, benzyl H), 
4.54 (t, 12H, -TrzCH2CH2O-, -OCH2CH2Trz-), 4.36 (br s, 6H, -NHCH2Trz-), 4.01 - 3.48 [m, 63H, SA (8-H, NH, 7-H, 4-H, 
9-H, 5-H, 6-H,) SCH2C=C, EG spacer], 2.75 (dd, 3J = 14 Hz , 2J = 7 Hz , 3H, SA 3-He), 2.19 (br t, 6H, -CH2CH2CONH-), 
2.01 (s, 9H, SA, -NHCOCH3), 1.89 (br s, 6H, -CH2CH2CONH-), 1.79 (t, 3J = 14 Hz, 3H, SA 3-Ha); 13C NMR (125 MHz, 
D2O) : δ (ppm) = 175.67, 175.17, 172.72, 144.59, 128.86, 128.38, 127.62, 124.9, 124.5, 84.3, 75.0, 71.4, 69.8, 69.6, 
68.8, 68.7, 68.2, 62.9, 56.9, 51.8, 40.3, 34.6, 29.9, 23.3, 22.2; IR (film): ν = 3280, 2927, 1705, 1645, 1548, 1114, 1059, 
1027, 954 cm−1; HRMS (ESI): m/z: calculated for C93H143N25O38S3: 2335.9080 [M+Na+-1]; found: 2335.8764.  
 
Hemagglutinnation inhibition assay 
Inhibitors were twofold serially diluted in PBS. Then, 4 HAU X31 virus containing approximately 4∙107 virus particles 
were added to all the wells. The amount of virus particles per volume was estimated as published by Desselberger et 
al.[20] After 30 min incubation under slight agitation at rt, 50 µl of a 1 % human erythrocyte solution (German Red Cross, 
~2∙106 cells/µl) was added, gently mixed, and incubated for 60 min at rt. The inhibitor constant KiHAI, reflects the lowest 
inhibitor concentration, which is necessary to achieve full inhibition of virus induced hemagglutination. To check for full 
hemagglutination inhibition, the microtiter plate was tilted by 60° to cause droplet formation from the red blood cell 
pellet.[21]  
 
Microscale thermophoresis (MST) 
Measurements have been performed using a Monolith NT.115 instrument (Nanotemper) and standard glass capillaries. 
For safety reasons, X31 was inactivated with UV light for 5 min on ice. Then the envelope of viruses (1 mg/ml protein) 
was labeled at 20 µM R18 for 30 min at rt under gentle shaking. Unbound R18 was removed under centrifugation at 
20,000 x g for 5 min. The resuspended virus was filtered through a 0.45 µm filter (Millipore) to remove virus aggregates. 
To quantify the amount of virus and to check whether the prepared virus was still able to bind, a hemagglutination assay 
was performed. Each inhibitor was twofold serially diluted and mixed with equal amounts of X31 (4 HAU). After a short 
incubation, then the inhibitor-virus mix was loaded on glass capillaries and measured at rt for initial fluorescence (5 s) 
and change in fluorescence over time (30 s) with the thermophoresis measurement (MST power: 80%, green LED 
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power 100%). The T-jump with thermophoresis was used for analysis. Data were analyzed by with Graph pad Prism 5 
using a one-sided fit with a cooperativity factor of 1. In order to determine the noise level, triplicates of the same virus 
dilution were measured leading to ΔF = 5 FU. For safety reasons X31 was inactivated with UV light for 5 min on ice. The 
change in ﬂuorescence was expressed as ΔFnorm (‰) and represented values after subtraction of background and 
correlation to the initial ﬂuorescence before IR laser activation. 
 
 
Molecular Dynamics Simulation Set-up 
All-atom molecular dynamics (MD) simulations were performed for the monovalent counterparts of compounds 8 and 9 
(later referred as ligands 8 and 9, respectively) in explicit water (TIP3P water model),[22] using the GROMACS 5.0.2 
simulation package.[23] The initial structures of the ligands were drawn in Marwin Sketch (MarvinSketch (version 6.2.2, 
calculation module  developed by ChemAxon), 
http://www.chemaxon.com/products/marvin/marvinsketch/, 2014). Both ligands were parametrized in Acpype.[24] The 
topologies of the ligands 8 and 9 were generated according to the General Amber Force Field (GAFF).[25] The semi-
emipirical quantum chemistry program SQM[26] was used to assign the partial charges with the AM1-BC level of theory.  
The systems were minimized in vacuum with the steepest decent algorithm[27] (emtol = 1000.0 (kJ/mol)/nm, nsteps = 
50,000). 4069 and 14441 water molecules were added to solvate the ligands 8 and 9, respectively, in a dodecahedron 
box (volume of the ligand 8 box 130.51 nm3, volume of the ligand 9 box 443.76 nm3). Then solvated ligands were 
brought to another round of minimization with the same parameters, followed by two equilibration runs, first in the NVT 
ensemble at 300 K (V-rescale thermostat,[28] time constant = 0.1 ps), and then in NPT ensemble (Parrinello-Rahman 
barostat,[29] reference pressure = 1 bar, time constant = 2 ps) for 100 ps respectively. Five starting structures per ligand 
were randomly taken from the NPT equilibration run and later used in the subsequent MD runs. The production runs 
were simulated in the NPT ensemble (temperature 300 K, pressure 1 bar). The covalent bonds to all hydrogen atoms 
were constrained with the LINCS algorithm[30] (lincs iter = 1, lincs order = 4), allowing for an integration time step of 2 fs. 
Newton’s equations of motion were integrated with a leap-frog scheme. The cut-off for Lennard-Jones interactions was 
set to 1 nm. The electrostatic interactions were treated with the particle-mesh ewald (PME) algorithm[31] with a real 
space cut off 1 nm, a Fourier grid spacing of 0.16 nm, and an interpolation order of 4. Periodic boundary conditions 
were applied in all three dimensions. The solute coordinates were written to the trajectory file every 1 ps. In total, 1 µs of 
the simulations were obtained for each ligand. 
 
Molecular Dynamics Data Analysis 
The respective distances used to characterize ligands 8 and 9 were obtained with the GROMACS command 
g_mindist. Then, they were visualized with an in-house MATLAB (Darden, T.; York, D.; Pedersen, L. J. Chem. Phys. 
1993, 98, 10089 (https://doi.org/10.1063/1.464397) script. The intramolecular hydrogen bond networks were computed 
with GROMACS command g_hond, while the radius of gyration was extracted from the respective trajectories with 
GROMACS command g_gyrate. 
Supporting Information 
Details on the synthesis of heterobifunctional oligoethylene spacers, sialic acid derivative, and control molecule 24. 
Model for trivalent and divalent sialoside binding. 
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